Evidence map›Paper›PMID 37145930›Full record

ArticleThe Journal of infectious diseases2023

Pathogenesis of Aerosolized Ebola Virus Variant Makona in Nonhuman Primates.

Abhishek N Prasad, Karla A Fenton, Krystle N Agans, Viktoriya Borisevich, Courtney Woolsey, Jason E Comer, Natalie S Dobias, Jennifer E Peel, Daniel J Deer, Joan B Geisbert and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Abhishek N PrasadDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Karla A FentonDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Krystle N AgansDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Viktoriya BorisevichDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Courtney WoolseyDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Jason E ComerDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Natalie S DobiasDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Jennifer E PeelDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Daniel J DeerDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Joan B GeisbertDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
William S LawrenceDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Robert W CrossDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Thomas W GeisbertDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
The University of Texas Medical Branch at Galveston · US

Funding

Regulatory Compliance Core - Galveston National Laboratory BSL4 OperationsUC7AI094660 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Dennis A Bente · 2011 to 2026
$208.8M
PROVIDE RABBITS, RATS, IMCE, HAMSTERS, GERBILS, AND GUINEA PIGS27307C0009 · NIEHS · PI MARSION, LESLIE · 2007 to 2007
$540k
NIAID NIH HHS UC7 AI094660NIEHS NIH HHS 27307C0009
6 · The paper itself

Abstract

backgroundHighly pathogenic filoviruses such as Ebola virus (EBOV) hold capacity for delivery by artificial aerosols, and thus potential for intentional misuse. Previous studies have shown that high doses of EBOV delivered by small-particle aerosol cause uniform lethality in nonhuman primates (NHPs), whereas only a few small studies have assessed lower doses in NHPs.

methodsTo further characterize the pathogenesis of EBOV infection via small-particle aerosol, we challenged cohorts of cynomolgus monkeys with low doses of EBOV variant Makona, which may help define risks associated with small particle aerosol exposures.

resultsDespite using challenge doses orders of magnitude lower than previous studies, infection via this route was uniformly lethal across all cohorts. Time to death was delayed in a dose-dependent manner between aerosol-challenged cohorts, as well as in comparison to animals challenged via the intramuscular route. Here, we describe the observed clinical and pathological details including serum biomarkers, viral burden, and histopathological changes leading to death.

conclusionsOur observations in this model highlight the striking susceptibility of NHPs, and likely humans, via small-particle aerosol exposure to EBOV and emphasize the need for further development of diagnostics and postexposure prophylactics in the event of intentional release via deployment of an aerosol-producing device.

Indexed as

EbolavirusHemorrhagic Fever, EbolaAerosolsAnimalsHumansMacaca fascicularisViral LoadAerosols

Identifiers

PMID37145930
PMCPMC10651212
OpenAlexW4372271645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.